Phocas Financial Corp’s Supernus Pharmaceuticals SUPN Stock Holding History

Phocas Financial Corp’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.8M	Sell	60,253 -3,160	-5%	-$152K	0.39%	105
2026 Q1	$3.28M	Sell	63,413 -17,907	-22%	-$912K	0.51%	81
2025 Q4	$4.04M	Buy	+81,320	New	+$3.95M	0.53%	77
2025 Q2	–	Sell	-102,550	Closed	-$3.36M	–	155
2025 Q1	$3.36M	Sell	102,550 -5,929	-5%	-$210K	0.51%	82
2024 Q4	$3.92M	Buy	+108,479	New	+$3.82M	0.52%	83
2023 Q4	$3.52M	Sell	121,559 -35,507	-23%	-$941K	0.46%	96
2023 Q3	$4.33M	Sell	157,066 -150	-0.1%	-$4.57K	0.63%	73
2023 Q2	$4.73M	Sell	157,216 -878	-0.6%	-$30.7K	0.65%	72
2023 Q1	$5.73M	Sell	158,094 -16,852	-10%	-$648K	0.82%	49
2022 Q4	$6.24M	Buy	174,946 +42,348	+32%	+$1.47M	0.9%	41
2022 Q3	$4.49M	Buy	132,598 +26,493	+25%	+$862K	0.7%	65
2022 Q2	$3.07M	Buy	+106,105	New	+$3.04M	0.46%	93

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Phocas Financial Corp's SUPN Position: Q2 2026 in Review

Phocas Financial Corp reduced its Supernus Pharmaceuticals (SUPN) stake by 5% in Q2 2026, selling an estimated $152K and leaving 60,253 shares worth $2.8M. The position accounts for 0.39% of the portfolio, ranked #105.

Phocas Financial Corp first reported a position in SUPN in Q2 2022 and has held it in 12 quarters since. The position peaked at $6.24M in Q4 2022. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Phocas Financial Corp held 60,253 shares of Supernus Pharmaceuticals worth $2.8M as of Q2 2026.
Phocas Financial Corp sold 3,160 Supernus Pharmaceuticals shares in Q2 2026, an estimated $152K.
Supernus Pharmaceuticals made up 0.39% of Phocas Financial Corp's portfolio in Q2 2026, its #105 holding.
Phocas Financial Corp first reported a position in Supernus Pharmaceuticals in Q2 2022 and has held it in 12 quarters since.
Phocas Financial Corp's Supernus Pharmaceuticals position peaked at $6.24M in Q4 2022.
334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Phocas Financial Corp's 13F filing for Q2 2026, filed 31 Jul 2026.